Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Astellas licenses GI candidate to new Drais virtual company Seldar

Executive Summary

In a deal structured similarly to one formed between the firms two months ago, Astellas Pharma Inc. and Drais Pharmaceuticals Inc. will ally in the development and commercialization of Astellas’ Phase I bombesin BB2 receptor antagonist ASP7147 for irritable bowel syndrome with diarrhea.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)
    • Reverse Licensing

Related Companies